About Flashpoint Therapeutics
Flashpoint Therapeutics is a Healthcare company based in Palo Alto (United States) founded in 2022 by Adam Margolin, Chad Mirkin, and Michelle Teplensky. Flashpoint Therapeutics is developing nanotherapeutic candidates that can deliver precise RNA, DNA, and peptide payloads to specific cells at the right time. Flashpoint Therapeutics has raised $10 million across 1 funding round from investors including Beta Lab. Its chief executive, as recorded, is Adam Margolin. Its focus areas include Biopharma Outsourcing, CDMO, Small Molecules & Peptides and Formulation. Its competitors include DNA Nanobots and OSEM.
Company details
Flashpoint Therapeutics is a company that is developing nanotherapeutic candidates to deliver precise RNA, DNA, and peptide payloads to specific cells at the right time. They are pioneering nanotechnology-enabled medicines.
- Headquarters Palo Alto, United States
- Founders Adam Margolin, Chad Mirkin, Michelle Teplensky
- SectorsHealthcare
- Website flashpoint.bio
- Social LinkedIn
- Total Equity Funding$10M (USD)
in 1 rounds
- Latest Funding Round$10M (USD), Seed
Oct 2023
- Investors
Funding Insights of Flashpoint Therapeutics
Flashpoint Therapeutics has successfully raised a total of $10M through 1 strategic funding round. The most recent funding activity was a Seed round of $10 million completed in October 2023. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $10M
- Total Rounds 1
- Last Round Seed — $10M
- First Round $10M
(Oct 2023)
- Investors Count 1
All 1 funding rounds of Flashpoint Therapeutics with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Oct 2023 | $10M | Seed | – | Beta Lab | – |
1 investors in total: 1 institutional.
Investors in Flashpoint Therapeutics
Flashpoint Therapeutics has secured backing from 1 investor, including venture fund investors. Prominent investors backing the company include Beta Lab.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Beta Lab is recognized as a leading investment firm focused on global business growth. | blab.com.sa | Riyadh, Saudi Arabia |
Investor details for Flashpoint Therapeutics
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Flashpoint Therapeutics
3 people are tracked at Flashpoint Therapeutics (3 in leadership).
| Name | Role | Group |
|---|---|---|
Adam Margolin | Co-Founder & CEO | Leadership |
Chad Mirkin | Co-Founder | Leadership |
Michelle Teplensky | Co-Founder | Leadership |
Complete people profiles for Flashpoint Therapeutics
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Flashpoint Therapeutics
2 dated milestones of Flashpoint Therapeutics across 1 years, from founding to its latest funding, stage changes and deals.
- Founded Flashpoint Therapeutics is founded.
- Funding First funding round of $10.0M.
Competitors of Flashpoint Therapeutics
Flashpoint Therapeutics has 2 listed competitors in our database. They include DNA Nanobots and OSEM.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| dnananobots.com | 2021 | Powell, United States | Targeted chemotherapy, vaccines, and gene therapy are delivered via nanotechnology. | |||
| osem.bio | 2023 | Marina Del Rey, United States | An automated platform utilizing microfluidics for biopharmaceutical processes. |
Detailed competitors of Flashpoint Therapeutics
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Flashpoint Therapeutics
The website of Flashpoint Therapeutics (flashpoint.bio) receives about 2.4K visits a month.
- Monthly visits2.4K
▲ 8.8% vs previous month
Top companies in Biopharma Outsourcing & Drug Delivery
3 companies that operate in the same segment as Flashpoint Therapeutics (Biopharma Outsourcing & Drug Delivery) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Suite solutions are provided for payers and healthcare providers. | 1998 | Princeton, New Jersey, United States | USD 220 M | USD 374.1 M | 4,490 | |
Wearable insulin infusion systems are developed for diabetes patients. | 2000 | Boston, Massachusetts, United States | USD 120.4 M | USD 2.71 B | 3,900 | |
Developer of small-molecule drugs | 1991 | Los Angeles, California, United States | USD 50 M | USD 348.97 M | 407 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Flashpoint Therapeutics
Complete news archive for Flashpoint Therapeutics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Flashpoint Therapeutics
Flashpoint Therapeutics was founded in 2022 and raised its 1st funding round 1 year after it was founded.
Flashpoint Therapeutics is headquartered in Palo Alto, United States. It is registered at Palo Alto, California, United States.
Adam Margolin is the CEO of Flashpoint Therapeutics, as recorded in our data. They have also founded this company.
Flashpoint Therapeutics is a funded company, having raised a total of $10M across 1 funding round to date. The company's 1st funding round was a Seed of $10M, raised on Oct 2023.
Flashpoint Therapeutics is a company that is developing nanotherapeutic candidates to deliver precise RNA, DNA, and peptide payloads to specific cells at the right time. They are pioneering nanotechnology-enabled medicines.
Flashpoint Therapeutics's top competitors include DNA Nanobots and OSEM.
Flashpoint Therapeutics has 1 investor. Key investors include Beta Lab.